(Q36283448)

13 August 2017

1 reference

title

Cardiac involvement in the antiphospholipid syndrome (English)

1 reference

13 August 2017

3

M D Lockshin

1 reference

13 August 2017

1

F Tenedios

1 reference

13 August 2017

D Erkan

2

1 reference

13 August 2017

publication date

1 January 2005

1 reference

13 August 2017

1 reference

13 August 2017

volume

14

1 reference

13 August 2017

issue

9

1 reference

13 August 2017

page(s)

691-696

1 reference

The role of complement in the antiphospholipid syndrome

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2202OA

Antiphospholipid syndrome: multiple mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2202OA

Inflammatory response and the endothelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2202OA

Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2202OA

Evaluation of cardiac abnormalities and embolic sources in primary antiphospholipid syndrome by transesophageal echocardiography

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2202OA

Valvular heart disease in the primary antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2202OA

Valvular dysfunction in antiphospholipid syndrome: prevalence, clinical features, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2202OA

Cardiac abnormalities in systemic lupus erythematosus. Association with raised anticardiolipin antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2202OA

Association of antibodies against phospholipids with heart valve disease in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2202OA

Increased morbidity and mortality in patients with antiphospholipid syndrome undergoing valve replacement surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2202OA

Are oxidized LDL/beta2-glycoprotein I complexes pathogenic antigens in autoimmune-mediated atherosclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2202OA

Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2202OA

Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2202OA

Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2202OA

Coronary and valvular syndromes and antiphospholipid antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2202OA

Prevalence of an abnormal ankle-brachial index in patients with primary antiphospholipid syndrome: preliminary data

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2202OA

Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2202OA

Antiphospholipid antibodies after myocardial infarction and their relation to mortality, reinfarction, and non-haemorrhagic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2202OA

Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2202OA

Right ventricular diastolic dysfunction in patients with anticardiolipin antibodies and antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2202OA

M mode and Doppler echocardiographic assessment of left ventricular diastolic function in primary antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2202OA

Diastolic dysfunction is a feature of the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2202OA

Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2202OA

Catastrophic antiphospholipid syndrome. Clinical and laboratory features of 50 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2202OA

The lung in the antiphospholipid syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2202OA

Management of pregnancy in women with pulmonary hypertension secondary to SLE and anti-phospholipid syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2202OA

Cardiac disease in the antiphospholipid syndrome: recommendations for treatment. Committee consensus report

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F0961203305LU2202OA

10.1191/0961203305LU2202OA

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference